Cogent Biosciences (COGT) | Stock Overview & Key Data
Cogent Biosciences Performance Comparison
Stock Range
Today's Range
Low: $11.10
High: $11.64
on August 1, 2025
52 Week Range
Low: $3.72
High: $12.97
on April 9, 2025
on July 21, 2025
All-Time High: $70.64 on August 6, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.6B
EPS
-1.97
P/E Ratio (TTM)
-5.88
Forward P/E
-4.96
P/B Ratio
11.72
PEG Ratio
-4.96
Div. Yield
N/A
ROE
-84.04%
Beta
0.314
Debt to Equity
7.80
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-47.45%
Return on Equity (TTM)
-84.04%
EBITDA
$-286.0M
Net Income (TTM)
$-269.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences COGT | 1.59B Small-cap | -5.55% | 57.89% | 102.49% | 26.81% | 46.15% | 21.28% | -5.39% | 5.95% |
| Vertex VRTX | 118.67B Large-cap | -1.60% | 2.20% | -7.36% | -1.75% | 13.89% | -6.54% | 60.45% | 69.28% |
| Regeneron REGN | 58.89B Large-cap | -0.75% | 4.48% | -5.28% | -16.19% | -21.86% | -48.36% | -8.92% | -9.89% |
| Harmony Biosciences HRMY | 1.98B Small-cap | -8.32% | 7.40% | 15.20% | -11.75% | -1.23% | 6.17% | -34.48% | -4.44% |
| Denali Therapeutics DNLI | 1.95B Small-cap | -1.68% | -3.66% | -16.31% | -38.46% | -35.51% | -38.55% | -62.41% | -57.48% |
| Amicus Therapeutics FOLD | 1.95B Small-cap | 4.29% | 8.22% | -5.39% | -34.44% | -32.12% | -37.30% | -48.11% | -58.99% |
Ownership & Short Interest
Insider Ownership
0.04%
Institutional Ownership
103.74%
Shares Short
14M
Short Ratio
2.76
Short % of Shares Outstanding
11.21%
Average 10-Day Volume
2M
Average 90-Day Volume
4M
Cogent Biosciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Cogent Biosciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is COGT's 52-week high and low?
- In the last 52 weeks, Cogent Biosciences reached a high of $12.97 (on July 21, 2025) and a low of $3.72 (on April 9, 2025).
- What is the market cap and P/E ratio for COGT?
- Curious about Cogent Biosciences's size and valuation? Its market capitalization stands at 1.59B. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.88, and the forward P/E (looking ahead) is -4.96.
- Does COGT pay dividends? If so, what's the yield?
- As for dividends, Cogent Biosciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Cogent Biosciences's main competitors or similar companies to consider before investing?
When looking at Cogent Biosciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX118.67B Healthcare Biotechnology -6.54% 60.45% Regeneron
REGN58.89B Healthcare Biotechnology -48.36% -8.92% Harmony Biosciences
HRMY1.98B Healthcare Biotechnology 6.17% -34.48% Denali Therapeutics
DNLI1.95B Healthcare Biotechnology -38.55% -62.41% Amicus Therapeutics
FOLD1.95B Healthcare Biotechnology -37.30% -48.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Cogent Biosciences Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Cogent Biosciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -84.04%, the Debt to Equity ratio from the most recent quarter is 7.80, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for COGT?
- Looking at Cogent Biosciences's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of COGT stock is held by insiders and institutions?
- Wondering who owns Cogent Biosciences stock? Company insiders (like executives and directors) hold about 0.04% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 103.74%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.